Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical trial of AMG510 (Sotorasib) in stage III unresectable NSCLC KRAS p.G12C patients and medically ineligible for concurrent chemo-radiotherapy (MERIT-lung)

Next Previous
Trial Profile

Phase II clinical trial of AMG510 (Sotorasib) in stage III unresectable NSCLC KRAS p.G12C patients and medically ineligible for concurrent chemo-radiotherapy (MERIT-lung)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sotorasib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms MERIT-lung

Most Recent Events

  • 10 Apr 2025 Planned number of patients changed from 43 to 19.
  • 03 Aug 2023 Planned End Date changed from 30 Dec 2028 to 31 Dec 2028.
  • 03 Aug 2023 Planned primary completion date changed from 30 Dec 2027 to 31 Dec 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top